Haemonetics Corp
haemonetics.comHaemonetics Corp (NYSE: HAE) is a medical technology company that develops and sells devices, disposables, and software for blood and plasma management. It generates revenue through the sale of capital equipment and high-volume single-use disposables, with software solutions sold to plasma collectors, blood centers, and hospitals. The company operates in three segments: Plasma, Blood Center, and Hospital. The Hospital segment, which includes Interventional Technologies and Blood Management Technologies product lines, represented 44.1% of total revenue in fiscal 2026, up from 34.9% in fiscal 2024. The Plasma segment serves biopharmaceutical and plasma collection companies, while Blood Center addresses blood collection groups and independent blood centers. Haemonetics sells in approximately 90 countries, using a direct sales force and independent distributors across approximately 87 of those markets. Customers include biopharmaceutical companies, hospitals, group purchasing organizations, and national health organizations.
Products & Services
Plasma segment: plasma collection devices and disposables, donor management software. Blood Center segment: blood collection and processing devices and disposables for plasma, red cells, and platelets. Hospital segment: Interventional Technologies (Vascular Closure including VASCADE MVP XL launched August 2024 and Vivasure acquisition completed January 2026, Sensor-Guided Technologies, Esophageal Protection) and Blood Management Technologies (TEG hemostasis analyzers, Cell Salvage, SafeTrace Tx transfusion management software, BloodTrack blood management software, BloodTrack HaemoBank device).
Revenue Model
Haemonetics earns revenue through sales of capital devices paired with recurring single-use disposables, and through software licensing and solutions including donor management, transfusion management, and hemostasis monitoring software sold to plasma collectors, blood centers, and hospitals.
Customers & Markets
Customers include biopharmaceutical companies, blood collection groups, independent blood centers, hospitals and hospital service providers, group purchasing organizations, and national health organizations. End markets include plasma collection, cardiovascular surgery, organ transplantation, trauma, electrophysiology, structural heart procedures, and perioperative blood management.
Geographic Exposure
Products sold in approximately 90 countries as of the 10-K filed 2026-05-20, with independent distributors in approximately 87 of those countries. Manufacturing presence includes a facility in Tijuana, Mexico. The company is exposed to currency fluctuation, geopolitical risk, and evolving U.S. tariff policy.
Financial Snapshot
Loading...
